CRL
Charles River Laboratories
294.40$
+6.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 19.0% | 19.6% | 20.5% | 18.9% | 18.7% | 18.6% | 19.9% | 19.4% | 20.4% | 20.3% | 19.3% | 20.3% | |
| 2.1% | 3.4% | 4.0% | 2.3% | 2.6% | 2.6% | 3.0% | 2.4% | 2.8% | 3.0% | 2.5% | 2.5% | |
| 2.1% | 3.4% | 4.0% | 2.3% | 2.6% | 2.6% | 3.0% | 2.4% | 2.8% | 3.0% | 2.5% | 2.5% | |
| 10.5% | 9.5% | 9.7% | 9.6% | 9.4% | 9.6% | 10.0% | 10.2% | 9.8% | 9.9% | 9.1% | 9.4% | |
| 3.9% | 4.6% | 4.4% | 4.4% | 4.2% | 3.7% | 3.8% | 3.7% | 4.0% | 4.2% | 4.7% | 4.6% | |
| 25.0% | – | – | – | 25.3% | 26.8% | 26.2% | 26.4% | 26.2% | 28.3% | – | – | |
| 37.9% | 37.8% | 37.7% | 38.7% | 39.0% | 37.8% | 37.9% | 38.8% | 38.9% | 38.7% | 39.3% | 40.8% | |
| 11.7% | 10.5% | 10.2% | 10.1% | 9.7% | 9.6% | 8.6% | 8.0% | 7.6% | 4.8% | 3.2% | 3.4% | |
| 56.0% | 55.4% | 54.6% | 52.5% | 52.2% | 53.4% | 57.2% | 55.0% | 54.1% | 55.0% | 61.3% | 62.2% | |
| 13.1% | 12.9% | 11.7% | 11.9% | 12.6% | 13.2% | 13.9% | 14.3% | 14.9% | 15.7% | 14.1% | 15.1% | |
| 5.6% | 5.4% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | – | – | |
| 1.8% | 2.1% | 1.6% | 1.7% | 1.7% | 1.9% | 2.0% | 1.9% | 2.3% | 2.1% | 1.7% | 1.9% | |
| 33.1% | 32.3% | 32.6% | 30.3% | 29.1% | 29.8% | 33.1% | 30.8% | 29.1% | 29.6% | 34.5% | 34.8% | |
| 43.5% | 43.9% | 44.7% | 46.8% | 47.3% | 46.0% | 42.1% | 44.4% | 45.3% | 44.4% | 38.0% | 37.7% | |
| 22.6% | 23.0% | 24.0% | 25.8% | 26.5% | 24.1% | 24.2% | 25.0% | 25.9% | 19.5% | 17.8% | 18.2% | |
| 0.7% | 0.6% | 0.6% | 0.7% | 0.6% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.6% | 0.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.